Abstract: A method for use in performing a prostatectomy procedure on a patient. The method includes: identifying a dominant lesion in a prostate gland, wherein the prostate gland is contained within a prostate capsule; cutting outside the perimeter of a first portion of the prostate capsule corresponding to a region of the prostate gland in which the dominant lesion is located, and inside the perimeter of a second portion of the prostate capsule corresponding to a region of the prostate gland in which the dominant lesion is not located; and removing the first portion of the prostate capsule from the patient's body and preserving the second portion of the prostate capsule in the patient's body.

Abstract: A method for diagnosing and treating prostate cancer in a human subject is provided, the method comprises: a. providing a sample of prostate tissue, blood, or urine from the subject; b. determining the level of expression of SEQ ID NO: 1 and the expression of SEQ ID NO: 5 in the sample, wherein an increased level of expression of SEQ ID NO:1 and a reduced level of expression of SEQ ID NO: 5 in the sample is indicative of a diagnosis that the subject has prostate cancer; and c. administering a therapeutically effective prostate cancer treatment selected from the group consisting of an androgen receptor (AR)-targeted therapy, an antimicrotubule agent, an alkylating agent and an anthracenedione to the subject to treat the prostate cancer in the human subject diagnosed with prostate cancer.

Abstract: A method for diagnosing and treating prostate cancer in a human subject is provided, the method comprises: a. providing a sample of prostate tissue, blood, or urine from the subject; b. determining the level of expression of SEQ ID NO: 1 and the expression of SEQ ID NO: 5 in the sample, wherein an increased level of expression of SEQ ID NO:1 and a reduced level of expression of SEQ ID NO: 5 in the sample is indicative of a diagnosis that the subject has prostate cancer; and c. administering a therapeutically effective prostate cancer treatment selected from the group consisting of an androgen receptor (AR)-targeted therapy, an antimicrotubule agent, an alkylating agent and an anthracenedione to the subject to treat the prostate cancer in the human subject diagnosed with prostate cancer.

Abstract: A cooling syringe and method are provided for inducing selective hypothermia of a body tissue during minimally invasive surgery. The cooling syringe includes an elongated, hollow housing configured to receive a cooling substance, the housing having a proximal end and a distal end. An actuator is at least partially received within the housing, the actuator including an elongated shaft having a proximal end and a distal end. The actuator includes a handle portion at the shaft proximal end and an end cap received on the shaft distal end, the shaft and end cap together forming a plunger. A guidance cap having a central channel is received on the shaft and disposed at a proximal end thereof. The actuator is movable with respect to the guidance cap and within the housing to dispense the cooling substance from the housing distal end.

Abstract: In some embodiments, the invention comprises methods and compositions for the assessment of prostate cancer in humans by determining the level of certain markers indicative of prostate cancer in vivo, including but not limited to SEQ ID NO:1 and SEQ ID NO:5, in tissue, blood, urine, or other biological samples.